Furthermore, the lack of change in the production of the lymphocyte growth factors, IL-7 and GM-CSF, over the treatment and remission phases of MM suggests that aberrant cytokine expression may help sustain the MM-CSC population during remission, a speculation supported by previously identified MM-CSC growth conditions in 3-D cultures [30]. This evidence concerns the gene IL7 and Miyoshi myopathy.